{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T02:26:01Z","timestamp":1790821561261,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,22]],"date-time":"2025-11-22T00:00:00Z","timestamp":1763769600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.neurot.2025.e00812","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T05:46:44Z","timestamp":1764827204000},"page":"e00812","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Switching from anti-CD20 therapies to cladribine and vice versa \u2013 Analysis of a German relapsing multiple sclerosis cohort"],"prefix":"10.1016","volume":"23","author":[{"given":"Franz Felix","family":"Konen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Pfeuffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantin Fritz","family":"Jendretzky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Gehring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birte","family":"Elias-Hamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurt-Wolfram","family":"S\u00fchs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Halle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korbinian","family":"Brand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Lichtinghagen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"Willemse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Pawlitzki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kuhle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven G.","family":"Meuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Kleinschnitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Refik","family":"Pul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Skripuletz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurot.2025.e00812_bib1","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1056\/NEJMra1401483","article-title":"Multiple sclerosis","volume":"378","author":"Reich","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2025.e00812_bib2","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1016\/S0140-6736(18)30481-1","article-title":"Multiple sclerosis","volume":"391","author":"Thompson","year":"2018","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00812_bib3","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1001\/jamaneurol.2018.4905","article-title":"Clinical Outcomes of Escalation vs Early Intensive Disease-Modifying Therapy in PatientsWith Multiple Sclerosis","volume":"76","author":"Harding","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00812_bib4","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00812_bib5","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJMoa0902533","article-title":"CLARITY Study Group. A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis","volume":"362","author":"Giovannoni","year":"2010","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.neurot.2025.e00812_bib6","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1177\/1352458517727603","article-title":"Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study","volume":"24","author":"Giovannoni","year":"2018","journal-title":"Mult Scler"},{"issue":"9805","key":"10.1016\/j.neurot.2025.e00812_bib7","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/S0140-6736(11)61649-8","article-title":"Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial","volume":"378","author":"Kappos","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.neurot.2025.e00812_bib8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","article-title":"Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis","volume":"29","author":"Comi","year":"2019","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2025.e00812_bib9","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1004795","article-title":"Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic","volume":"14","author":"de S\u00e8ze","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00812_bib10","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1177\/13524585211010294","article-title":"Analysis of frequency and severity of relapses in multiple sclerosis patients treated with cladribine tablets or placebo: The CLARITY and CLARITY Extension studies","volume":"28","author":"De Stefano","year":"2022","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurot.2025.e00812_bib11","series-title":"Real-world outcomes of people with relapsing multiple sclerosis switching from natalizumab or ocrelizumab to cladribine tablets. Poster presented at: ACTRIMS forum 2024","author":"Okuda","year":"2024"},{"issue":"15_supplement","key":"10.1016\/j.neurot.2025.e00812_bib12","first-page":"94","article-title":"Short-term efficacy and safety outcomes after switching from anti-CD20 DMTs to cladribine in a real-world setting (5389)","author":"O\u2019Neill","year":"2020","journal-title":"Neurology"},{"issue":"Suppl 1","key":"10.1016\/j.neurot.2025.e00812_bib13","first-page":"629","article-title":"Treatment patterns prior to and post cladribine in patients with multiple sclerosis","volume":"29","author":"Ellenberger","year":"2022","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00812_bib14","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1007\/s10072-022-06582-y","article-title":"Systematic literature review of immunoglobulin trends for anti-CD20 monoclonal antibodies in multiple sclerosis","volume":"44","author":"Saidha","year":"2023","journal-title":"Neurol Sci"},{"key":"10.1016\/j.neurot.2025.e00812_bib15","article-title":"Molecular mechanisms of immunosenescence and inflammaging: relevance to the immunopathogenesis and treatment of multiple sclerosis","volume":"12","author":"Perdaens","year":"2021","journal-title":"Front Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00812_bib16","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40120-024-00603-y","article-title":"Narrative Review on the Use of Cladribine Tablets as Exit Therapy for Stable Elderly Patients with Multiple Sclerosis","volume":"13","author":"de Seze","year":"2024","journal-title":"Neurol Ther"},{"key":"10.1016\/j.neurot.2025.e00812_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.106145","article-title":"De-escalation from anti-CD20 to cladribine tablets in multiple sclerosis: A pilot study","volume":"92","author":"Sacco","year":"2024","journal-title":"Mult Scler Relat Disord"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00812_bib18","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/13524585231161494","article-title":"Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY\/CLARITY Extension cohort of CLASSIC-MS: An ambispective study","volume":"29","author":"Giovannoni","year":"2023","journal-title":"Mult Scler"},{"issue":"8","key":"10.1016\/j.neurot.2025.e00812_bib19","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S1474-4422(21)00095-8","volume":"20","author":"Wattjes","year":"2021","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurot.2025.e00812_bib20","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1212\/WNL.33.11.1444","article-title":"Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS)","volume":"33","author":"Kurtzke","year":"1983","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.neurot.2025.e00812_bib21","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaneurol.2020.1568","article-title":"Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials","volume":"77","author":"Kappos","year":"2020","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurot.2025.e00812_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105015","article-title":"Prevalence of 2-year \"No evidence of disease activity\" (NEDA-3 and NEDA-4) in relapsing-remitting multiple sclerosis. A real-world study","volume":"79","author":"Bazzurri","year":"2023","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2025.e00812_bib23","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211066751","article-title":"Smouldering multiple sclerosis: the 'real MS","volume":"15","author":"Giovannoni","year":"2022","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00812_bib24","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","article-title":"NfL Reference Database in the Swiss Multiple Sclerosis Cohort Study Group. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study","volume":"21","author":"Benkert","year":"2022","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.neurot.2025.e00812_bib25","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1001\/jamaneurol.2022.5250","article-title":"Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis","volume":"80","author":"Meier","year":"2023","journal-title":"JAMA Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2025.e00812_bib26","first-page":"517","article-title":"Consensus of a group of professional societies and diagnostic companies on guidelines for interim reference ranges for 14 proteins in serum based on the standardization against the IFCC\/BCR\/CAP Reference Material (CRM 470)","volume":"34","author":"Dati","year":"1996","journal-title":"International Federation of Clinical Chemistry. Community Bureau of Reference of the Commission of the European Communities. College of American Pathologists. Eur J Clin Chem Clin Biochem."},{"issue":"12","key":"10.1016\/j.neurot.2025.e00812_bib27","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.1002\/eji.202170126","article-title":"Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition)","volume":"51","author":"Cossarizza","year":"2021","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.neurot.2025.e00812_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.cca.2025.120447","article-title":"Validation and generation of age-specific reference intervals for a new blood neurofilament light chain assay","volume":"577","author":"Booth","year":"2025","journal-title":"Clin Chim Acta"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00812_bib29","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/ana.27096","article-title":"Cohort study (SMSC). Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis","volume":"97","author":"Benkert","year":"2024","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2025.e00812_bib30","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1212\/WNL.0000000000205238","article-title":"Prospective longitudinal study of cladribine tablets (CLADB study) demonstrates sustained reduction in kappa free light chains in relapsing multiple sclerosis at 96 weeks","volume":"102","author":"Ammoscato","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.neurot.2025.e00812_bib31","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1343892","article-title":"CSF levels of Chitinase3like1 correlate with early response to cladribine in multiple sclerosis","volume":"15","author":"Marastoni","year":"2024","journal-title":"Front Immunol"},{"issue":"1-2","key":"10.1016\/j.neurot.2025.e00812_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jns.2013.06.003","article-title":"Impact of cladribine therapy on changes in circulating dendritic cell subsets, T cells and B cells in patients with multiple sclerosis","volume":"332","author":"Mitosek-Szewczyk","year":"2013","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurot.2025.e00812_bib33","article-title":"Sustained effects on immune cell subsets and autoreactivity in multiple sclerosis patients treated with oral cladribine","volume":"15","author":"Holm","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00812_bib34","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200048","article-title":"MAGNIFY-MS Study Group. Specific Patterns of Immune Cell Dynamics May Explain the Early Onset and Prolonged Efficacy of Cladribine Tablets: A MAGNIFY-MS Substudy","volume":"10","author":"Wiendl","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00812_bib35","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1186\/s12974-023-02859-x","article-title":"Transcriptome alterations in peripheral blood B cells of patients with multiple sclerosis receiving immune reconstitution therapy","volume":"20","author":"Hecker","year":"2023","journal-title":"J Neuroinflammation"},{"key":"10.1016\/j.neurot.2025.e00812_bib36","doi-asserted-by":"crossref","DOI":"10.1177\/17562864231211077","article-title":"Single-cell profiling reveals preferential reduction of memory B cell subsets in cladribine patients that correlates with treatment response","volume":"16","author":"Teschner","year":"2023","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurot.2025.e00812_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102279","article-title":"The ocrelizumab phase II extension trial suggests the potential to improve the risk-benefit balance in multiple sclerosis","volume":"44","author":"Baker","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurot.2025.e00812_bib38","series-title":"Qualit\u00e4tshandbuch MS\/NMOSD\/MOGAD","year":"2024"},{"key":"10.1016\/j.neurot.2025.e00812_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103076","article-title":"French Group for Recommendations in Multiple Sclerosis (France4MS) and the Soci\u00e9t\u00e9 Fran\u00e7aise de la Scl\u00e9rose En Plaques (SFSEP). How to switch disease-modifying treatments in multiple sclerosis: Guidelines from the French Multiple Sclerosis Society (SFSEP)","volume":"53","author":"Bigaut","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"10.1016\/j.neurot.2025.e00812_bib40","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s40120-022-00422-z","article-title":"Treatment with Cladribine Tablets Beyond Year 4: A Position Statement by Southeast European Multiple Sclerosis Centers","volume":"12","author":"Habek","year":"2023","journal-title":"Neurol Ther"},{"issue":"13","key":"10.1016\/j.neurot.2025.e00812_bib41","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1080\/14656566.2022.2106783","article-title":"Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4","volume":"23","author":"Meuth","year":"2022","journal-title":"Expert Opin Pharmacother"},{"issue":"5","key":"10.1016\/j.neurot.2025.e00812_bib42","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41582-024-00955-x","article-title":"Neurofilaments as biomarkers in neurological disorders - towards clinical application","volume":"20","author":"Khalil","year":"2024","journal-title":"Nat Rev Neurol"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925002909?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747925002909?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T04:01:12Z","timestamp":1772856072000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747925002909"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1878747925002909"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00812","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Switching from anti-CD20 therapies to cladribine and vice versa \u2013 Analysis of a German relapsing multiple sclerosis cohort","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2025.e00812","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00812"}}